User:Mr. Ibrahem/Bosutinib
 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Bosulif |
| AHFS/Drugs.com | Monograph |
| License data | |
| Routes of administration | By mouth |
| Drug class | Tyrosine kinase inhibitor[1] |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 94–96% |
| Metabolism | By CYP3A4, to inactive metabolites |
| Elimination half-life | 22.5±1.7 hours |
| Excretion | Foecal (91.3%) and renal (3%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C26H29Cl2N5O3 |
| Molar mass | 530.45 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Bosutinib codenamed SKI-606, marketed under the trade name Bosulif, is a medication used to treat chronic myelogenous leukemia (CML).[2] Specifically it is used for cases that are Philadelphia chromosome positive.[2] It is taken by mouth.[2]
Common side effects include diarrhea, rash, nausea, tiredness, liver problems, respiratory tract infection, fever, and headache.[2] Other side effects may include bone marrow suppression, heart damage, swelling, and kidney problems.[2] Use in pregnancy may harm the baby.[2] It is a tyrosine kinase inhibitor that blocks BCR-ABL and src.[1]
Bosutinib was approved for medical use in the United States in 2012 and Europe in 2013.[2][1] In the United Kingdom 4 weeks of treatment costs the NHS about £3,400 as of 2021.[3] This amount in the United States is about 17,000 USD.[4]
References[edit]
- ^ a b c "Bosulif". Archived from the original on 14 November 2021. Retrieved 11 January 2022.
- ^ a b c d e f g h i "DailyMed - BOSULIF- bosutinib monohydrate tablet, film coated". dailymed.nlm.nih.gov. Archived from the original on 25 March 2021. Retrieved 11 January 2022.
- ^ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1015. ISBN 978-0857114105.
- ^ "Bosulif Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 22 January 2021. Retrieved 11 January 2022.